Lilly gets Indian emergency use nod for Covid-19 antibody drug combination

Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle the second wave. A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use, the company's Indian unit said.

source https://timesofindia.indiatimes.com/india/lilly-gets-indian-emergency-use-nod-for-covid-19-antibody-drug-combination/articleshow/83140037.cms